Related Experiment Videos
Sulfasalazine and dermatitis herpetiformis
Elizabeth Willsteed1, Michael Lee, Li Chuen Wong
1Department of Dermatology, Royal North Shore Hospital, St Leonards, New South Wales, Australia.
The Australasian Journal of Dermatology
|April 22, 2005
Summary
Sulfasalazine offers a promising treatment option for refractory dermatitis herpetiformis. This drug, a source of sulfapyridine, showed positive results in cases unresponsive to dapsone and gluten-free diets.
Area of Science:
- Dermatology
- Clinical Therapeutics
Background:
- Dermatitis herpetiformis (DH) poses a therapeutic challenge when standard treatments like dapsone and gluten-free diets are ineffective or not tolerated.
- Dapsone is a primary treatment, but adverse effects or lack of response necessitates alternative therapies.
Observation:
- This study presents three cases of dermatitis herpetiformis managed with sulfasalazine.
- Two patients intolerant to dapsone experienced rapid clinical improvement with sulfasalazine, with no reported side effects.
- A third patient with presumed DH showed an excellent response but discontinued sulfasalazine due to side effects after six weeks.
Findings:
- Sulfasalazine, metabolized to sulfapyridine, demonstrated efficacy in managing difficult-to-treat dermatitis herpetiformis.
- The therapeutic potential of sulfasalazine is highlighted, especially for patients unable to use dapsone.
Implications:
- Sulfasalazine should be considered a viable therapeutic option for managing refractory dermatitis herpetiformis.
- Further investigation into sulfasalazine's efficacy and safety profile in DH management is warranted.